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Abstract
Numerous reports have documented the beneficial effects of dietary docosahexaenoic acid (DHA) on beta-amyloid
production and Alzheimer’s disease (AD). However, none of these studies have examined and compared DHA, in
combination with other dietary nutrients, for its effects on plaque pathogenesis. Potential interactions of DHA with other
dietary nutrients and fatty acids are conventionally ignored. Here we investigated DHA with two dietary regimes; peptamen
(pep+DHA) and low fat diet (low fat+DHA). Peptamen base liquid diet is a standard sole-source nutrition for patients with
gastrointestinal dysfunction. Here we demonstrate that a robust AD transgenic mouse model shows an increased tendency
to produce beta-amyloid peptides and amyloid plaques when fed a pep+DHA diet. The increase in beta-amyloid peptides
was due to an elevated trend in the levels of beta-secretase amyloid precursor protein (APP) cleaving enzyme (BACE), the
proteolytic C-terminal fragment beta of APP and reduced levels of insulin degrading enzyme that endoproteolyse betaamyloid. On the contrary, TgCRND8 mice on low fat+DHA diet (based on an approximately 18% reduction of fat intake)
ameliorate the production of abeta peptides and consequently amyloid plaques. Our work not only demonstrates that DHA
when taken with peptamen may have a tendency to confer a detrimental affect on the amyloid plaque build up but also
reinforces the importance of studying composite lipids or nutrients rather than single lipids or nutrients for their effects on
pathways important to plaque development.
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as insulin degrading enzyme (IDE) [10] is also accepted to
aggravate AD pathogenesis, resulting in neuronal loss with
consequential dementia and death [2].
Numerous studies in cell culture and animal models have
traditionally evaluated the effects of dietary docosahexaenoic acid
(DHA) alone; the most studied omega-3 polyunsaturated FA
(PUFA) [11–15]. Diet usually consists of complex combinations of
lipids or nutrients that might act synergistically or antagonistically
and show a greater effect on disease than any single lipid or
nutrient. The complexity of human diet, especially the high
synergistic or antagonistic correlation among the effects of various
nutrients and foods, makes it difficult to examine their separate
effects [Willett, 1998 #2555]. In the current study, we investigated
DHA with two dietary regimes; peptamen (pep+DHA) and low fat
diet (low fat+DHA) for its effects on the pathological basis of AD in
an AD mouse model. Peptamen is a standard sole-source nutrition
for patients with gastrointestinal dysunction including HIV/AIDS
[16] as well as Crohn’s disease [17], stomach cancer [18],
malignant gastroduodenal tumor [19], choledocholithiasis [20],
acute pancreatitis [21], radiation enteritis and cystic fibrosis [22].
The testing of the potential effects of the combined use of

Introduction
Gastric intolerance is one of the side effects of various
treatments currently available for Alzheimer’s disease (AD) [1].
Similarly, nutritional alterations and gastrointestinal dysfunction is
common in various ailments including human immunodeficiency
virus (HIV) infection (HIV) and so as in HIV associated dementia
(HAD), which represents the most severe form of HIV-associated
neurocognitive disorders [2]. HAD is commonly characterized by
amyloid plaques deposition and other associated Alzheimer’s
disease (AD)-like brain pathology [3–7], resulting in neuronal loss
with consequential dementia and death [8]. The amyloid plaques
consist of different forms of the beta-amyloid (Ab) derivatives of
the amyloid precursor protein (APP) [9]. Through amyloidogenic
pathway APP is first cleaved into C-terminal fragment b (CTFb)
by b-secretases, which is then cleaved by c-secretase to produce
Ab40 and Ab42 (reviewed in [Selkoe, 1998 #395]); the most
common constituents of amyloid plaques. Where as nonamyloidogenic pathway initiated by a-secretases generates soluble
APPa (sAPPa) and CTFa (reviewed in [Selkoe, 1998 #395]).
Impaired functioning of proteins responsible for Ab clearance such
PLoS ONE | www.plosone.org
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content of the high omega-3 diet of Greenland Eskimos, who have
among the highest dietary intakes of omega-3 FA in the world
[25]. In the present trial, we did not evaluate energy intake since
the interventions were designed to be non-isocaloric. Special care
was taken to make sure that the levels of vitamin E were identical
across the diet groups.

peptamen diet supplemented with DHA therefore has important
implications not only for AD but also for a significant number of
patients suffering from HAD or long-term HIV survivors with comorbid AD in the future [23]. Surprisingly, in contrast to low
fat+DHA mice, TgCRND8 mice on pep+DHA diet showed an
aggravated drift to produce beta-amyloid peptides and amyloid
plaques. Our results suggest that beneficial effects of protective
FAs (DHA) cannot be achieved perhaps without eliminating the
deleterious fats from the diet and yet the amount of protective FAs
(DHA) in the diet needs to be regulated.

Fatty acid analysis
FAs in the brain were isolated and methylated according to
Moser and Moser [26]. The FA methyl ester (FAME) mixture was
then resuspended in hexane and analyzed by gas chromatographymass spectroscopy (GC-MS). GC-MS analysis was performed on a
Hewlett-Packard Series II 5890 gas chromatograph coupled to an
HP-5971 mass spectrometer equipped with a Supelcowax SP-10
capillary column. FAME mass was determined by comparing
areas of unknown FAMEs to that of a fixed concentration of 17:0
internal standard.

Materials and Methods
Mice, treatment and tissue preparation
Ethics Statement. All experimental procedures were
performed according to the animal care guidelines of the
University of Western Ontario as approved by the University
Committee on Research Ethics (UCRE; approval ID; 2004-06506). All studies were performed on 5 month-old congenic C57BL/
6J male mice heterozygous for transgene (Tg)CRND8 (which
express a double-mutant form of human APP 695; Swedish
(K670N/M671L) and Indiana (V717F) and demonstrate severe
AD-like amyloid pathogenesis, including Ab brain deposits as early
as 3 months of age [24]. Mice used in these studies were housed on
12 h light/dark cycles. At 3 weeks of age TgCRND8 mice were
provided ad libitum access to water and one of three diets (n = 6 for
each diet) until 20–21 weeks of age at which time they were
sacrificed by cervical decapitation. Brains were rapidly removed
and sectioned sagitally into hemibrains. One hemibrain was used
for the biochemical (protein, RNA and ELISAs) and lipid analyses.
The other hemibrain was fixed in 10% neutral buffered formalin
and 0.1 M phosphate buffered saline (PBS; 8.1 mM disodium
hydrogen phosphate, 1.5 mM potassium dihydrogen phosphate,
137 mM sodium chloride, and 2.7 mM potassium chloride,
pH 7.4) for 48 h and then stored at 4uC in PBS and 1% sodium
azide until used for immunohistochemistry.

Immunohistochemistry and image analysis
Plaque density was measured using immunohistochemistry with
a biotinylated-4G8 monoclonal antibody (SIG-39240, Signet
Laboratories, Dedham, MA), directed against amino acids 17–24
of the b-amyloid peptide. Briefly, brain tissue was fixed in 10%
neutral buffered formalin, antigen retrieval performed with 70%
formic acid (20 min., room temperature), endogenous mouse IgG
was blocked using the MOM kit (Dako), followed by incubation
with biotinylated-4G8 at a dilution of 1:2000 and colour
developed with DAB. Images were captured through an Olympus
DP digital camera attached to an IX70 inverted microscope
(Olympus) using Image Pro Plus Software. The images were
analyzed using a macro to measure specifically stained area and
total area. Plaques were examined (using 106 objective) in three
brain regions (ten field each to cover the entire region): parietal
cortex, hippocampus and thalamus: 0.5–0.9 mm, 0.9–1.35 mm,
and 1.35–1.8 mm mediolateral from the bregma (Mouse Brain
Atlas, Franklin and Paxinos 2007) on 40 mm thick rostral (cross)
sections (6/region) of each hemisphere. Plaque density was
calculated by dividing total area of Ab-positive structures by per
millimeter of each region analyzed (in square micrometers).

Dietary manipulations
The experimental diet involved the following four groups: (1)
Conventional mouse chow (chow; PicoLab Mouse Chow Diet 20;
Purina Mills, St. Louis, MO) (2) Peptamen base nutrition diet
(pep; Nestle Nutrition, Canada). Peptamen is a ready to use,
isotonic, lactose-and gluten-free, whey peptide based isocaloric
(1 kcal/ml) formula including 40 g of protein per 1000 kcal.
Proteins are hydrolyzed into peptides (1% of free amino acids,
40% of peptides made of ,10 amino acids, 46% of peptides of 10–
40 amino acids, and 13% of peptides of .40 amino acids). Seventy
percent of lipids are in the form of medium-chain triglycerides
(11 g of long-chain triglycerides and 26 g of medium-chain
triglycerides/1000 kcal) (3) peptamen base supplemented with
45.2 mg/20 ml/day/mouse of high level of algal origin DHA
(pep+DHA; Neuromins, Pure Encapsulations, Inc., Sudbury,
USA), (4) Soybean oil (1%), high protein, low fat diet (low
fat+DHA; Research Diets Product L10047, New Brunswick).
Composition of the low fat diet was as follows: alcohol extracted
casein (304.7 g/kg), DL-methionine (4.6 g/kg), sucrose (279.3 g/
kg), maltodextrin (Fro-Dex) (284.4 g/kg), vitamin Mix, V10001
(AIN-76A) (10.2 g/kg), mineral mix, S10001 (AIN-76A) (35.0 g/
kg), cellulose (40.6 g/kg), xanthan gum (8.6 g/kg), soybean oil
(10.2 g/kg) with DHA (Nu-Chek-Prep, Inc, USA). Low fat diet
was supplemented separately by the recommended amount of
essential linoleic (LA) and linolenic acids (LNA). In total, DHA
made up roughly 5.76% of the total fat intake/mouse/day, which
is almost half on a per weight basis to that of 13% omega-3 FA
PLoS ONE | www.plosone.org

Quantitative Western Blotting
Western blot to analyze proteins has been described previously
[27]. Blots were bound to anti-APP (1:15,000) from Sigma (A8717), anti-b-site APP cleaving enzyme-C terminal fragment
(BACE1-CTF) (1:1000; a gift from Dr. Michael Willem), anti-bactin (1:5000) from Santa Cruz (sc-1616), anti-insulin degrading
enzyme-1 (IDE-1) (1:4000; a gift from Dr. Dennis Selkoe) and antiprion protein (PrP) (1:5000, a gift from Dr. Alex Strom). Goat antirabbit (RPN4301) was used at 1:15,000 and sheep anti-mouse
(RPN4201) at 1:5000. Quantification was performed by using
Image Gauge software with densitometry scans from Western
blots.

Real-time RT-PCR
RNA isolation, reverse transcription and PCR conditions have
been described previously [27].The primers used are: TgAPP
forward: 59- GAT GAC GTC TTG GCC AAC ATG -39 and
reverse: 59- CGG AAT TCT GCA TCC AGA TTC AC -39
(308 bp product); murine APP: forward 59- CCG ACG ATG
TCT TGG CCA AC -39 and reverse: 59- CCG AAT TCT GCA
TCC ATC TTC AC -39 (310 bp product); PrP forward: 59- GGG
GAC AAC CTC ATG GTG GTA GT-39 and reverse: 59-TCC
ACT GGC CTG TAG TAC ACT TGG-39 (283 bp product); and
2
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b-actin forward: 59-TCG TGG GCC GCT CTA GGC ACC A-39
and reverse 59- GTT GGC CTT AGG GTT CAG GGG GG-39
(256 bp product). Data analysis was performed using the BioRad
GeneX.

on histopathological changes specifically that of 38% increase in
amyloid plaque density in the parietal cortex (17.3662.47 vs
12.5360.912, p = 0.11), 42% in hippocampus (19.9162.35 vs
13.9860.658, p = 0.051) and 96% in thalamic (5.1261.56 vs
2.6160.34, p = 0.16) regions of Tg/pep+DHA mice brains when
compared to Tg/chow mice brains, respectively (Fig. 1A & B).
Assuming that perhaps DHA and pep is not an ideal
combination to decrease amyloid pathology in TgCRND8 mice,
we designed ‘‘low-fat+DHA’’ diet, which was high in protein and
DHA and low in all deleterious fats to find out if DHA is still
detrimental. As expected, TgCRND8 mice on low fat+DHA diet
showed a significant decrease in the plaque density/mm2 of
parietal cortex: 5.560.19; p,0.01, hippocampus: 3.860.15;
p,0.001, and thalamus: 2.060.62; p,0.05 compared to
pep+DHA mice (Fig. 1A & B).

Ab sandwich ELISAs
Quantification of Ab40 and 42 productions in brain was done
by Signet ELISA methods. Briefly, parietal cortices of Tg mice
were homogenized in 1 ml of 70% formic acid (to dissolve Abpositive aggregates) and centrifuged at 100,0006g for 1 hr. The
supernatant was recovered and neutralized by a 20-fold dilution in
1 M Tris base buffer. Formic acid extracts of Ab were diluted up
to 1:100 with diluents supplied with the kit (Signet Laboratories,
Dedham, MA). Ab40 and Ab42 levels in the cortex were
quantitatively measured by sandwich ELISA system using
monoclonal antibodies (SIG-38940 and SIG-38942, Signet
Laboratories, Dedham, MA). The Ab values were calculated by
comparison with a standard curve of synthetic Ab40 and Ab42
peptides, according to the protocol provided by the manufacturer.

Effects on Ab levels
Levels of cerebral Ab peptides were examined by ELISA, which is a
standard method of detecting brain Ab peptides in transgenic mice. In
agreement with its effect on plaque burden, pep+DHA supplementation resulted in 32% increase in Ab40 levels (4.7360.55 vs
3.5860.18 ng/ml, p = 0.075) and 57% increase in Ab42 (5.7261.09
vs 3.6360.57 ng/ml, p = 0.109) levels in the Tg/pep+DHA mice
brains compared to Tg/chow mice (Fig. 1C). Ab40 was significantly
(37%) lower in Tg/pep mice (3.4360.43 ng/ml, p = 0.089) compared
to Tg/pep+DHA mice. As expected, hippocampus and adjacent
cortices of mice on low-fat+DHA diet demonstrated a significant 97%
decrease in the levels of Ab42 peptides (2.960.53; ng/ml; p,0.05)
compared to pep+DHA mice (Fig. 1C).

Statistics
All values were presented as mean 6 standard error of the mean
(S.E.M.). Protein densitometric and Ab40 and Ab42 levels and
plaque density were compared by Student’s unpaired two-tailed t
tests. Ratios of CTFs to FA change were analyzed using one-way
ANOVA analysis. The significance level was chosen to be 0.05
(p#0.05). Correlations between parameters were tested by linear
regression analysis.

Results
Effects on a-secretase pathway

General health

Western blot showed 15% increase in the levels of membrane
bound FL-APP (8.9561.16 vs 7.7560.47, p = 0.058) and 47%
decrease in the levels of APP-CTFa (0.7260.30 vs 1.5260.17,
p = 0.06) in the frontal cortices of Tg/pep+DHA mice compared
to Tg/chow mice, respectively (Fig. 2A).

All animals were routinely monitored for weight gain/loss (by
weighing) and gastrointestinal problems (by monitoring feces and
urine for texture and colour), agitation as well as sleep and general
motor disorders. All animals were in good health with no obvious
signs of any distress. No significant differences were observed in
body weights between the Tg/chow and Tg/pep mice. Though
Tg/pep+DHA mice were over 8% (27.763.37 vs 25.5364.91,
p = 0.0718) heavier than Tg/chow and Tg/pep mice, however, it
did not reach to statistical significance. All animals were in good
health with no obvious signs of disease.

Effects on b-secretase pathway
Western blot showed 43% increase in the levels of BACE
(6.7360.96 vs 4.6960.26, p = 0.08) with the corresponding 33%
increase in the levels of APP-CTFb (5.060.52 vs 3.7560.36,
p = 0.098) in Tg/pep+DHA mice compared to Tg/chow mice,
respectively (Fig. 2A). Though there was no significant difference
in BACE levels between Tg/pep+DHA and Tg+pep mice,
however, CTFb levels were significantly (p,0.05) lower in Tg/
pep mice compared to Tg/pep+DHA mice.

Effects on CNS lipid profile
GC-MS analysis of CNS lipids showed 6% increase in omega-3
FAs (DHA) in Tg/pep+DHA mice (1296.5621.79 nmol/g, p,0.05)
compared to Tg/pep (1221.92618.66 nmol/g) mice. Where as Tg/
low fat+DHA mice (1383.17623.97 nmol/g, p,0.05) showed a
6.68% increase in brain DHA content compared to Tg/pep+DHA
mice. Tg/low fat+DHA mice showed a 6.62% decrease in linoleic
acid (99.7963.929 nmol/g, p,0.05) compared to Tg/pep+DHA
(106.8662.81 nmol/g, p,0.05) mice, which had 7.72% lower
linoleic acid compared to Tg/pep mice (115.861.199 nmol/g,
p,0.05). The content of saturated fatty acid (SFA) was around
37.48% more in Tg/pep+DHA mice (16876.2362070.32 nmol/g,
p,0.05) compared to Tg/pep mice (12277.26385.08 nmol/g,
p,0.05). However, Tg/low fat+DHA mice (10149.426
790.33 nmol/g, p,0.05) had 39.8% lower SFA compared to Tg/
pep+DHA mice. This data also indicates that 1761 weeks is a
reasonable time to alter CNS fatty acid concentration.

Effects on Ab metabolism
To determine the relatively larger increases in Ab levels
compared to the smaller increases in APP-CTFb, we next
examined the levels of IDE (proteins responsible for the clearance
of Ab). Western blot showed 54% reduction in the IDE levels
(3.5161.40 vs 6.4360.42, p = 0.093) in Tg/pep+DHA mice
compared to Tg/chow mice, respectively (Fig. 2A).

Effects on PrP levels
The CRND8 transgenic APP expression is driven by the PrP
promoter. To support the absence of the effect of different diets on
PrP activity - the protein levels of PrP among different groups were
investigated. As shown in Fig. 2A, the different dietary regimens
did not cause any significant change in PrP levels, thereby
supporting that both the pep and pep+DHA diets did not
influence the levels of APP transgene expression.

Effects on plaque pathology
Immunohistochemistry and image analysis showed that pep+DHA
supplementation, though non-significant, showed a detrimental trend
PLoS ONE | www.plosone.org
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Figure 1. Effects of pep+DHA diet on amyloid plaques and Ab levels. A. Photomicrographs of Ab stained amyloid plaques in the Parietal
Cortex (PC), Hippocampus (HC) and Thalamus (TM) of Tg/chow, Tg/pep and Tg/pep+DHA mice. B. Plot shows quantitative analysis of amyloid
plaques density. C. ELISA results for Ab40 and Ab42 levels in the hippocampus and adjacent cortices of Tg/chow, Tg/pep, Tg/pep+DHA and Tg/low
fat+DHA mice. The mean 6 S.E.M. are shown for all plots, (n = 6 for each experiment), **p,0.01 and *p,0.05.
doi:10.1371/journal.pone.0024094.g001

correlation suggests that the activities of a and b-secretase enzymes
are affected by the CNS FAs levels. This influence of FA levels on
CTFb/CTFa ratio and consequently on Ab production can be
partly rationalized in that APP folding, directed trafficking to
proteosomal degradation or post-translational processing, as well

Effects on secretase products
Significant direct correlation (R2 = 0.96; p,0.05) was found
between increasing percentage distribution of CNS FAs versus the
ratios of the levels of secretase products; CTFb (generated by bsecretase) and CTFa (generated by a-secretase) (Fig. 3). This

PLoS ONE | www.plosone.org
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Figure 3. Effects of pep+DHA diet on a/b- secretase products.
Change in percentage distribution of total FA in the CNS (Table-1) was
plotted against CTFb/CTFa ratio (Figure 2) of Tg/chow, Tg/pep and Tg/
pep+DHA mice. Plot shows a decrease in CTFb/CTFa ratio with
increasing FA percentage distribution, *p,0.05. The mean 6 S.E.M. is
shown for, *p,0.05.
doi:10.1371/journal.pone.0024094.g003

effects of that particular diet. Instead, it is important to investigate
as well as discuss the optimal proportion of lipids/nutrients that
are frequently or seldom present in a diet and might offer the most
favorable biological synergy in relation to disease risk. For
instance, DHA demonstrates an overall drift towards detrimental
consequences - when it is administered with peptamen based
liquid - in pathways important to amyloid deposition. This drift
appears to be the result of a combination of several contributing
factors. First, in Tg/pep+DHA mice proteolytic processing of the
membrane-bound mature FL-APP was roughly augmented
leading to corresponding increases in APP-CTFb as compared
to their age-matched Tg/pep and Tg/chow controls. Since the
expression levels of the APP transgene and PrP promoter were
unchanged, the elevated trend in FL-APP protein is most likely the
result of its diminished degradation through the proteasomal
pathway [3] or its increased overall stability, implying that
pep+DHA diet may alter Ab generation either by altering APP
trafficking to secretase-containing compartments of the membrane
or secretase enzymatic activity itself. In keeping with the proposed
diminishment of degradation - precedence for the impact of
differential FAs on activity of the ubiquitin-proteasome pathway is
seen with other proteins [32], suggesting a physiological means to
regulate protein degradation where post-ER trafficking to either
the Golgi or proteosomes appears the underlying basis.
Secondly, the increase inclination in BACE levels is likely due to
the elevation of its FL-APP substrate - in agreement with a study
demonstrating a parallel increase in BACE with levels of FL-APP
[33]. Alternatively, since BACE is also degraded via the ubiquitinproteasome pathway [34] – the affect of pep+DHA supplement on
BACE levels may also be the result of diminished proteosomal
degradation, or a combination of the two. Nevertheless, given the
complexity of the in vivo system the actual basis of this effect would
be difficult if not impossible to ascertain.
Thirdly, and of particular significance, in Tg/pep+DHA mice pep+DHA enrichment resulted in a leaning towards augmentation
in Ab levels with 57% increase in Ab42 levels alone, more than

Figure 2. Effects of pep+DHA diet on protein levels. A. Western
blots of APP, BACE, APP-CTFs (a/b), IDE, PrP and b-actin protein levels in
the frontal cortices of Tg/chow, Tg/pep and Tg/pep+DHA mice.
Respective molecular weights (Kd) are shown on the left. Plot shows
quantitative analysis of protein levels as mean 6 S.E.M., (n = 6 for each
experiment, out of 6 only 3 animals each are shown for Tg/chow, Tg/
pep and Tg/pep+DHA mice in Western blots), ***p,0.001, **p,0.01
and *p,0.05.
doi:10.1371/journal.pone.0024094.g002

as cleavage by the secretases occurs within the milieu of specific
cellular membranes, and that their lipid architecture can affect
such activity and/or specificity.

Effects on endogenous APP, transgene and PrP gene
expressions
In order to investigate if pep and pep+DHA-induced increase in
APP levels is due to the altered transcription of APP gene (or PrP
gene; that derives the transcription of APP in TgCRND8 mice),
real-time RT-PCR was carried out. Fig. 4A showed that both the
pep and pep+DHA diets did not have any effect on the expression
levels of either CRND8 transgene-specific APP or endogenous
APP (Fig. 4A). Similar to PrP protein levels, the levels of PrP gene
were comparable across the groups (Fig. 4B).

Discussion
In this study, we reinforce our recent findings [28–31] that
physiological interaction among amalgamated mixtures of different FAs and/or nutrients in a diet, is critical for their impact on Ab
production/metabolism. Attributing the effects of a composite diet
to a single lipid alone may not be adequate to explain most of the
PLoS ONE | www.plosone.org
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Figure 4. Effects of pep+DHA diet on gene expression levels. Real-time RT-PCR of endogenous murine (m), CRND8 transgene-specific (Tg)
APP (A) and PrP (B) expression levels in Tg/chow, Tg/pep and Tg/pep+DHA mice, (n = 6 for each experiment, out of 6 only 1 animal is shown for each
group in PCR images). Plots show quantitative analysis (mean 6 S.E.M.) of b-actin normalized gene expression levels.
doi:10.1371/journal.pone.0024094.g004

would be expected by elevation of BACE and CTFb alone.
Consequently, the IDE levels were 54% reduced. IDE, which
appears to degrade intracellular Ab more effectively than does
neprilysin in both the detergent-soluble and insoluble fractions
[35].
Lastly, knowing that DHA and the brain are rich in oxidizable
PUFA we propose that perhaps (conversely to low fat+DHA diet)
some oxidizable constituents in peptamen diet might have caused
lipid membrane peroxidation and/or free radical damage to the
TgCRND8 mice brains [36] and antagonized the beneficial effects
of DHA either by increasing 4-hydroxynonenal (4-HNE), which
also reports to activate BACE indirectly [4], as observed in this
study or due to impaired Ab clearance, by somehow, reducing the
expression of the gene coding for IDE. Further in vitro studies in
neuronal cell lines would be required to clarify the basis of these
effects.
To evaluate if DHA has protective effect when supplemented
with a different composite nutritional base, we designed a diet high
in DHA but low in all deleterious associations with fats, and
showed that DHA indeed improve AD-type neuropathology in the
brains of TgCRND8 mice. Initially, by significantly decreasing
hippocampal Ab40 and Ab42 peptides levels and subsequently by
reducing amyloid plaque burden in cortex, hippocampus as well as
thalamus, endorsing our recent observation [31]. Though the
depletion of deleterious fat alone from the diet has shown reduced
amyloidosis [31], however, DHA supplementation even enhances
this protective effect further.
Peptamen is largely composed of ready to digest saturated fatty
acids, which apparently perhaps the reason for ,37% increase in
PLoS ONE | www.plosone.org

saturated fatty acids in Tg/pep+DHA mice. Tg/pep mice despite
having lowest omega-3 (DHA) levels among all mice groups did
not show as adverse plaque pathology as Tg/pep+DHA mice (with
significantly higher DHA levels than Tg/pep mice). Though Tg/
pep mice also showed an increase in saturated fatty acids,
however, not as huge as in Tg/pep+DHA mice, perhaps
supposedly due to the altered metabolism of saturated fatty acids
and DHA combination or due to the toxic interaction(s) between
DHA and it’s metabolites (like docosanoids) and saturated fatty
acids. Since the effects of such interactions are not fully
understood, the possibility that they may have adverse affects on
neuronal survival cannot be excluded. Linoleic acid deficiency
reflects a decrease in the omega-6 fatty acids as DHA has been
shown to down-regulate arachidonic acid (a member of omega-6)
pathway [37]. Therefore, higher levels of DHA were found to be
associated with lower levels of linoleic acid in the present study.
Moreover, a 2–9% increase in CNS DHA in the present study is
reasonable for 4–5 months treatment, because other studies report
that large (50–80%) [38] alteration in brain DHA requires
multiple generations of animals on DHA-depleted diets [39].
Our results suggest that perhaps the beneficial effects of DHA
can not be seen if they are supplemented without taking the effect
of other blended nutrients into consideration, especially if that
nutrient affects DHA antagonistically. Our findings also explain
reported controversial roles (detrimental or no effects) of diets rich
in omega-3 FAs on AD pathology. For instance, high omega-3 diet
was unable to improve cognitive performance in Tg mice in
multiple cognitive measures [15,40]. Further to this, the
administration of DHA, EPA or placebo to a group of mild to
6
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moderate AD subjects for 6 months resulted in no difference in
mini mental state examination (MMSE) or AD Assessment Scale
(ADAS) scores between the groups, despite daily omega-3 doses
that were many times higher than intake of omega-3 FA in fish
products [41]. Similarly, in non-transgenic rodents, there was no
cognitive benefit to supplementation with DHA after multiple
generations of omega-3 deficiency [42,43]. Likewise, Calon et al.,
reported no benefit in recognition/identification memory or
memory retention in either aged non-transgenic or aged Tg2576
mice supplemented with DHA following depletion [13]. In the
same way, MIDAS [44] and ADCS [45] DHA trials did not show
a benefit of DHA treatment in mild to moderate AD. Similarly an
increase in neuronal loss and prion formation [46] in cell-culture
AD models after DHA supplementation has also been reported.
Ironically, none of these studies had taken into account the role
and effect of other lipids or nutrients in the diet, that may had
either complemented or antagonized the effects of DHA on the
risk of AD.
In summary, our results from in vivo mouse studies opened up
new alleys in understanding the complex roles of PUFAs on the

biochemical mechanisms leading to amyloid plaque development
in patients suffering from co-morbidities. Present data do not
argue the protective effects of DHA (as shown by low fat+DHA
diet), rather strengthen ours [28–31,47] and others [48] previous
findings that we may have to focus on diet mixtures rather than
associating all effects to a single lipid or ingredient. We assume that
cellular/molecular homeostasis mechanisms can effectively offset
the effects of single lipids, rather than complex synergistic or
antagonistic changes exerted by mixture of diets. Further
controlled in vitro investigations, and particularly long-term
human-based retrospective studies would be required to confirm
the effect of pep+DHA diet and justify dietary modifications for
patients at risk of suffering from AD and HAD like co-morbidities.

Author Contributions
Performed the experiments: ZA MK LW. Analyzed the data: ZA RFR.
Contributed reagents/materials/analysis tools: ZA PM DW RFR. Wrote
the paper: ZA RFR. Conceived the experiments: RFR. Designed the
experiments: ZA.

References
19. Lykhach TV, Kliusov AM, Slobodianok ML (2004) [Experience of application
of the mixed enteral preparation Peptamen after performance of radical
operations for malignant gastroduodenal tumor]. Klin Khir (7): 5–7.
20. Kosyns’kyi OV (2004) [Dynamic of nonspecific markers of endogenous
intoxication under the influence of enteral probe nutrition in patients with
choledocholithiasis]. Klin Khir (7): 25–27.
21. Tiengou LE, Gloro R, Pouzoulet J, Bouhier K, Read MH, et al. (2006) Semielemental formula or polymeric formula: is there a better choice for enteral
nutrition in acute pancreatitis? Randomized comparative study. JPEN J Parenter
Enteral Nutr 30: 1–5.
22. Eckman EA, Cotton CU, Kube DM, Davis PB (1995) Dietary changes improve
survival of CFTR S489X homozygous mutant mouse. Am J Physiol 269:
L625–630.
23. Alisky JM (2007) The coming problem of HIV-associated Alzheimer’s disease.
Med Hypotheses 69: 1140–1143.
24. Chishti MA, Yang DS, Janus C, Phinney AL, Horne P, et al. (2001) Early-onset
amyloid deposition and cognitive deficits in transgenic mice expressing a double
mutant form of amyloid precursor protein 695. J Biol Chem 276: 21562–
21570.
25. Bang HO, Dyerberg J (1980) The bleeding tendency in Greenland Eskimos.
Dan Med Bull 27: 202–205.
26. Moser HW, Moser AB (1991) Measurement of saturated very long chain fatty
acids in plasma. In: Techniques in Diagnostic Human Biochemical
Genetics: A Laboratory Manual: Wiley-Liss Inc., New York. pp 177–191.
27. Brijbassi S, Amtul Z, Newbigging S, Westaway D, St George-Hyslop P, et al.
(2007) Excess of nicastrin in brain results in heterozygosity having no effect on
endogenous APP processing and amyloid peptide levels in vivo. Neurobiol Dis
25: 291–296.
28. Amtul Z, Uhrig M, Beyreuther K (2011) Additive effects of fatty acid mixtures
on the levels and ratio of amyloid beta40/42 peptides differ from the effects of
individual fatty acids. J Neurosci Res. doi: 10.1002/jnr.22706.
29. Amtul Z, Uhrig M, Rozmahel RF, Beyreuther K (2011) Structural Insight into
the Differential Effects of Omega-3 and Omega-6 Fatty Acids on the Production
of A{beta} Peptides and Amyloid Plaques. J Biol Chem 86: 6100–6107.
30. Amtul Z, Uhrig M, Supino R, Beyreuther K (2010) Phospholipids and a
phospholipid-rich diet alter the in vitro amyloid-beta peptide levels and amyloidbeta 42/40 ratios. Neurosci Lett 481: 73–77.
31. Amtul Z, Uhrig M, Wang L, Rozmahel RF, Beyreuther K (2011) Structural
basis for the detrimental effects of Arachidonic acid and it’s metabolites on the
production of amyloid peptides and plaques. Neurobiology of Aging;10.1016/
j.neurobiolaging. 07.014 2011:7.
32. Ando H, Wen ZM, Kim HY, Valencia JC, Costin GE, et al. (2006) Intracellular
composition of fatty acid affects the processing and function of tyrosinase
through the ubiquitin-proteasome pathway. Biochem J 394: 43–50.
33. Asberom T, Zhao Z, Bara TA, Clader JW, Greenlee WJ, et al. (2007) Discovery
of gamma-secretase inhibitors efficacious in a transgenic animal model of
Alzheimer’s disease. Bioorg Med Chem Lett 17: 511–516.
34. Christensen MA, Zhou W, Qing H, Lehman A, Philipsen S, et al. (2004)
Transcriptional regulation of BACE1, the beta-amyloid precursor protein betasecretase, by Sp1. Mol Cell Biol 24: 865–874.
35. Sudoh S, Frosch MP, Wolf BA (2002) Differential effects of proteases involved in
intracellular degradation of amyloid beta-protein between detergent-soluble and
-insoluble pools in CHO-695 cells. Biochemistry 41: 1091–1099.

1. Inglis F (2002) The tolerability and safety of cholinesterase inhibitors in the
treatment of dementia. Int J Clin Pract (Suppl 127): 45–63.
2. Shapshak P, Duncan R, Minagar A, Rodriguez de la Vega P, Stewart RV, et al.
(2004) Elevated expression of IFN-gamma in the HIV-1 infected brain. Front
Biosci 9: 1073–1081.
3. Everall IP, Hansen LA, Masliah E (2005) The shifting patterns of HIV
encephalitis neuropathology. Neurotox Res 8: 51–61.
4. Nath A, Hersh LB (2005) Tat and amyloid: multiple interactions. Aids 19:
203–204.
5. Rempel HC, Pulliam L (2005) HIV-1 Tat inhibits neprilysin and elevates
amyloid beta. Aids 19: 127–135.
6. Green DA, Masliah E, Vinters HV, Beizai P, Moore DJ, et al. (2005) Brain
deposition of beta-amyloid is a common pathologic feature in HIV positive
patients. Aids 19: 407–411.
7. Esiri MM, Biddolph SC, Morris CS (1998) Prevalence of Alzheimer plaques in
AIDS. J Neurol Neurosurg Psychiatry 65: 29–33.
8. Mattson MP (2004) Pathways towards and away from Alzheimer’s disease.
Nature 430: 631–639.
9. Miller DL, Papayannopoulos IA, Styles J, Bobin SA, Lin YY, et al. (1993)
Peptide compositions of the cerebrovascular and senile plaque core amyloid
deposits of Alzheimer’s disease. Arch Biochem Biophys 301: 41–52.
10. Farris W (2003) Insulin-degrading enzyme regulates the levels of insulin, amyloid
beta-protein, and the beta-amyloid precursor protein intracellular domain in
vivo. Proc Natl Acad Sci U S A 100: 4162–4167.
11. Lim GP, Calon F, Morihara T, Yang F, Teter B, et al. (2005) A diet enriched
with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an
aged Alzheimer mouse model. J Neurosci 25: 3032–3040.
12. Green KN, Martinez-Coria H, Khashwji H, Hall EB, Yurko-Mauro KA, et al.
(2007) Dietary docosahexaenoic acid and docosapentaenoic acid ameliorate
amyloid-beta and tau pathology via a mechanism involving presenilin 1 levels.
J Neurosci 27: 4385–4395.
13. Calon F, Lim GP, Yang F, Morihara T, Teter B, et al. (2004) Docosahexaenoic
acid protects from dendritic pathology in an Alzheimer’s disease mouse model.
Neuron 43: 633–645.
14. Hashimoto M, Hossain S, Agdul H, Shido O (2005) Docosahexaenoic acidinduced amelioration on impairment of memory learning in amyloid betainfused rats relates to the decreases of amyloid beta and cholesterol levels in
detergent-insoluble membrane fractions. Biochim Biophys Acta 1738: 91–98.
15. Schaefer EJ, Bongard V, Beiser AS, Lamon-Fava S, Robins SJ, et al. (2006)
Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia
and Alzheimer disease: the Framingham Heart Study. Arch Neurol 63:
1545–1550.
16. Salomon SB, Jung J, Voss T, Suguitan A, Rowe WB, Madsen DC (1998) An
elemental diet containing medium-chain triglycerides and enzymatically
hydrolyzed protein can improve gastrointestinal tolerance in people infected
with HIV. J Am Diet Assoc 98: 460–462.
17. Zoli G, Care M, Parazza M, Spano C, Biagi PL, et al. (1997) A randomized
controlled study comparing elemental diet and steroid treatment in Crohn’s
disease. Aliment Pharmacol Ther 11: 735–740.
18. Maev IV, Shaburov RI, Khenkina NA (2003) [Clinical assessment of the efficacy
of early enteral nutrition with the help of ‘‘peptamen’’ nutriment in patients who
underwent gastrectomy due to stomach cancer]. Eksp Klin Gastroenterol (3):
100–106.

PLoS ONE | www.plosone.org

7

September 2011 | Volume 6 | Issue 9 | e24094

Effects of Peptamen+DHA Diet on Amyloidosis

43. Ikemoto A, Ohishi M, Sato Y, Hata N, Misawa Y, et al. (2001) Reversibility of
n-3 fatty acid deficiency-induced alterations of learning behavior in the rat: level
of n-6 fatty acids as another critical factor. J Lipid Res 42: 1655–1663.
44. Yurko-Mauro K, McCarthy D, Bailey-Hall E, Nelson E, Blackwell A, M. I
(2009) Results of the MIDAS trial: effects of docosahexaenoic acid on
physiological and safety parameters in age-related cognitive decline. Vienna,
Austria.
45. Quinn J, Raman R, Thomas R, Ernstrom K, Yurko-Mauro K, et al. (2009) A
clinical trial of docosahexanoic acid (DHA) for the treatment of Alzheimer’s
disease. In: International Conference on Alzheimer’s Disease; 2009; Vienna,
Austria.
46. Bate C, Marshall V, Colombo L, Diomede L, Salmona M, et al. (2008)
Docosahexaenoic and eicosapentaenoic acids increase neuronal death in
response to HuPrP82-146 and Abeta 1–42. Neuropharmacology 54: 934–943.
47. Amtul Z, Westaway D, Cechetto DF, Rozmahel RF (2011) Oleic Acid
ameliorates amyloidosis in cellular and mouse models of Alzheimer’s disease.
Brain Pathol 21: 321–329.
48. Gu Y, Nieves JW, Stern Y, Luchsinger JA, Scarmeas N (2010) Food
combination and Alzheimer disease risk: a protective diet. Arch Neurol 67:
699–706.

36. Harman D, Hendricks S, Eddy DE, Seibold J (1976) Free radical theory of
aging: effect of dietary fat on central nervous system function. J Am Geriatr Soc
24: 301–307.
37. Kuehl FA, Jr., Egan RW (1980) Prostaglandins, arachidonic acid, and
inflammation. Science 210: 978–984.
38. Weisinger HS, Armitage JA, Jeffrey BG, Mitchell DC, Moriguchi T, et al. (2002)
Retinal sensitivity loss in third-generation n-3 PUFA-deficient rats. Lipids 37:
759–765.
39. Salem N, Jr., Litman B, Kim HY, Gawrisch K (2001) Mechanisms of action of
docosahexaenoic acid in the nervous system. Lipids 36: 945–959.
40. Arendash GW, Jensen MT, Salem N, Jr., Hussein N, Cracchiolo J, et al. (2007)
A diet high in omega-3 fatty acids does not improve or protect cognitive
performance in Alzheimer’s transgenic mice. Neuroscience 149: 286–302.
41. Freund-Levi Y, Eriksdotter-Jonhagen M, Cederholm T, Basun H, FaxenIrving G, et al. (2006) Omega-3 fatty acid treatment in 174 patients with mild to
moderate Alzheimer disease: OmegAD study: a randomized double-blind trial.
Arch Neurol 63: 1402–1408.
42. Gamoh S, Hashimoto M, Hossain S, Masumura S (2001) Chronic administration of docosahexaenoic acid improves the performance of radial arm maze task
in aged rats. Clin Exp Pharmacol Physiol 28: 266–270.

PLoS ONE | www.plosone.org

8

September 2011 | Volume 6 | Issue 9 | e24094

